Clover Health Investments, Corp. (NASDAQ:CLOV) Q3 2023 Earnings Call Transcript

Clover Health Investments, Corp. (NASDAQ:CLOV) Q3 2023 Earnings Call Transcript November 6, 2023

Clover Health Investments, Corp. beats earnings expectations. Reported EPS is $-0.08626, expectations were $-0.1.

Operator: Ladies and gentlemen, good afternoon, and welcome to the Clover Health Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the prepared remarks. [Operator Instructions]. As a reminder, today’s call is being recorded. I would now like to turn the call over to Ryan Schmidt, Investor Relations for Clover Health. Please go ahead, sir.

Ryan Schmidt: Good afternoon, everyone. Joining me on our call today to discuss the company’s third quarter results are Andrew Toy, Clover Health’s Chief Executive Officer; and Scott Leffler, the company’s Chief Financial Officer. You can find today’s press release and the accompanying supplemental slides in the Investor Events and Presentations section of our website at investors.cloverhealth.com. This webcast is being recorded and a replay will be available in the Investor Relations section of the Clover Health website. I’d also like to caution you that we may make forward-looking statements during today’s call that are subject to risks and uncertainties, including expectations about future performance. Factors that may cause actual results to differ materially from expectations are detailed in our SEC filings, including in the Risk Factors section of our most recent annual report on Form 10-K and other SEC filings.

Information about non-GAAP financial measures referenced, including a reconciliation of those measures to GAAP measures can be found in the earnings materials available on our website. With that, I’ll now turn the call over to Andrew.

Andrew Toy: Thank you, Ryan, and thanks everyone for joining us. Our results that we’ve reported today continue to highlight our progress towards sustained profitability and the great value derived from Clover Assistant. We’ve built upon our impressive first half of the year with our insurance segment once again delivering excellent results, driving strong overall company performance during the third quarter. Our results represent another proof point in our strategic shift to prioritize profitability this year, which in turn has led us to once again improve upon our full year 2023 guidance ranges. We believe that our Q3 results, coupled with our first half momentum further show our potential to achieve profitability next year on an adjusted EBITDA basis and without needing to raise additional capital.

Before I dive in more into our Q3 results, I hope that everyone was able to tune in to our Clover Assistant showcase last month, where we highlighted our cloud-based AI-powered platform and gave real-world examples of the impact we’ve seen through the use of Clover Assistant. I’ll touch more on this later in the call, but I encourage everyone to check out the replay of our event on our Investor Relations website if they haven’t done so already. Beginning first with our insurance results, we reported segment revenue of $301 million during the third quarter, representing an increase of 12% year-over-year. This segment continued its strong margin trajectory, delivering an MCR of 78.5%, a great improvement as compared to Q3 of 2022. I’m proud that our efforts this year to optimize our MA plan operations, grow revenue, and blunt MedEx growth continue to shine through in our results.

We’re constantly looking to optimize our capabilities, and I expect our MA plan improvements to only accelerate into next year. We believe the performance of our insurance segment further highlights how our technology and increasingly mature operations can truly support better care management within any MA population. As compared to other similar MA plans, our membership is more ethnically diverse and has a much higher percentage of members considered low income. Studies have shown that both low income and more diverse populations generally have a higher desire to use the power of our technology-centric model. Now, let’s move on to the recent publication of Star’s performance for the measurement year 2022 cycle. While we received stronger scores in many areas on our Star rating, we received an overall 3 Star rating for measurement year 2022, which dictates reimbursement for payment year 2025.

This result is obviously disappointing to us but we do see this cycle as an outlier. We came very close to 3.5 Star’s for measurement year 2022 even with the significant increase in cut points and the significant number of Star’s improvement efforts we deployed for measurement year 2023 plus the increase disappointed in the 3 Star rating, but see it as likely a one-year event for 2025. For that year, we’re committed to having strong financial momentum to mitigate its effects and we do not see it as a barrier to long-term sustained profitability. And we anticipate our Star performance improving in future measurement years. Shifting over to growth, similar to 2023, we intend to measure ourselves in terms of increasing top-line insurance revenue, and we are targeting high single-to low double-digit insurance segment revenue growth in 2024.

Expect us to continue to index on profitable growth through a combination of new member lives, churn reduction and per-member revenue initiatives. As our business continues to mature, we believe that this balanced approach is the right one to help us achieve our broader goal of reaching sustained profitability on an adjusted EBITDA basis next year. We’ll obviously have more to talk about regarding our annual enrollment performance at our next earnings. For our non-insurance segments, we reported a third quarter MCR of 104.1% on revenue of $176 million, bringing the year-to-date performance to an MCR of 99.7%. Even though we are continuing to target a non-insurance MCR below 100% for 2023, we continue to see challenges in the design of the program, and therefore are committed to right-sizing our exposure to value-based Original Medicare.

Consistent with that approach, we again expect a reduction in the number of participating physicians next year as we continue to evaluate this segment’s performance. For the future of this segment, we very much believe in our ability to use Clover Assistant to help physicians go to value-based care for non-Clover MA planned patients with Medicare. We started this with ACO Reach and Original Medicare, but in the last couple of years, we have seen clear evidence that we have great strength in Medicare Advantage total risk management. As such, while we will likely continue to closely manage our exposure to Original Medicare, you will see us increase investment in Medicare Advantage within our non-insurance segment. That is, we will look to enable physicians to use Clover Assistant across their entire MA panel for all MA plans and to be able to go to value-based risk on those lives.

We’re incredibly excited by this adjustment to the non-insurance strategy, and we look forward to talking about it more. With that, I’ll now hand it to Scott for the more detailed financial update.

Scott Leffler: Thanks, Andrew. I’ll first cover the third quarter financial highlights and then review our improved outlook for full year of 2023. Adjusted EBITDA significantly improved from a loss of $56 million in Q3 of last year to an adjusted EBITDA loss of $5 million in Q3 of this year, driven by strong insurance performance and a continued reduction in adjusted SG&A relative to the prior year period. For our insurance segment, MCR improved to 78.5% in Q3 from 86.3% in Q3 of last year, building on the strong momentum we delivered in the first half of this year. Our strong MCR performance was driven by revenue growth of 12% in Q3 to $301 million, and 15% growth year-to-date to $933 million. As we’ve mentioned in the past, we have continued to see favorable impacts from various operating initiatives all year, and these initiatives resulted in modest amounts of PPD from earlier in 2023 impacting Q3.

Our year-to-date MCR of 80.8% contains only minimal PPD and is a good representation of our underlying performance. During Q3, we experienced a similar medical cost trend to last quarter, with PMPM MedEx down 1% sequentially versus Q2, showing how our general medical expense trend is holding steady. We’re always focused on initiatives to manage MedEx through increasing impact from Clover Assistant, improvements to MA plan operations, including optimization of plan product design, network, payment integrity capabilities and expansion of our clinical initiatives. More specifically, our home care program continues to be a key lever contributing to the performance of the MA plan, where we’re focused on delivering in-home primary care powered by CA to our highest need numbers to reduce costly hospitalization and post-acute care utilization.

We’re increasingly enrolling higher risk new members into this program and are seeing lower inpatient admissions for participating members. We also benefited from being paid on 3.5 stars this year for our PPO plan, similar to earlier quarters this year. Our non-insurance segment revenue declined 70% versus the prior year period to $176 million, primarily driven by the smaller group of participant providers at the start of this year. Our non-insurance MCR in the third quarter was 104.1%, with a year-to-date MCR of 99.7%. This performance was relatively flat versus 104.2% for the third quarter of 2022. The deterioration from performance earlier in 2023 was largely driven by more conservative assumptions relating to benchmark views and determining performance under the program.

To reiterate Andrew’s earlier comments, we intend to improve the segment’s performance with further reductions in our ACO Reach participation in 2024. We believe this should reduce total participating physicians by approximately 40% beginning in 2024. I also wanted to provide an update regarding settlement on our 2022 performance for the non-insurance segment. As a reminder, there is a significant lag between the time we book profits or losses under the program versus when that performance is settled in cash with CMS. We’ve received the final settlement report from CMS for the 2022 performance year and expect to settle it during Q4. We currently estimate the total settlement amount owed to CMS as being approximately $147 million, $52 million of which accounts for our shared loss.

The remainder of the settlement relates to repayment of working capital obligations. Third quarter adjusted SG&A improved to $68 million, a 6% reduction year-over-year from $73 million in Q3 of 2022. We continue to see a favorable impact this quarter from some of the cost savings initiatives reported earlier this year. The UST HealthProof transition is actively underway for many of our MA Plan operations, with most of the benefits still yet to be realized starting in 2024. That said, many of the mission-critical workstreams are already configured into the UST ecosystem. This includes operations related to claims, new member enrollment, welcome kits, call center, and administrative functions, to name a few. And we believe this sets us up for a successful changeover in 2024.

We remain excited to take advantage of the economies of scale and operational efficiencies that we expect our partnership with UST HealthProof will capture and still expect to realize the full savings originally compensated from the initiative. Turning to the balance sheet, we finished the third quarter with restricted and unrestricted cash equivalents and investments, totaling $672 million on a consolidated basis with $308 million at the parent entity and unregulated subsidiary level. Our strong Q3 performance is another important step in the right direction to achieve sustainable profitability. I’m proud of the continued step change improvement in our insurance business this quarter, driving favorable adjusted EBITDA performance and giving us confidence that our results this year are sustainable.

We believe that this positions us well to achieve profitability in 2024 for the full year on an adjusted EBITDA basis. I believe that we’re progressing well on our mission to improve our financial performance so that we do not need any additional capital. Finally, I’ll provide an update to our full year 2023 guidance. This guidance is reflective of a certain amount of conservatism in Q4, in consideration of typical seasonality risk in Q4. We are narrowing our revenue guidance for the insurance line of business to between $1.21 billion and $1.23 billion. We are improving insurance MCR guidance to a range of 81% to 82%. We are maintaining our previous non-insurance revenue guidance at a range of $750 million to $800 million and MCR of 98% to 100%.

We are also improving our adjusted SG&A to between $310 million and $315 million. These changes resulted in improved adjusted EBITDA guidance of between negative $55 million and negative $80 million. In conclusion, we delivered another durable proof point this quarter on our path to profitability, we significantly improved adjusted EBITDA continued momentum in our insurance results with strong insurance and MSR and further reduction in adjusted SG&A from our previous initiatives. I believe that our great execution this year coupled with our updated expectations for the full year, should set us up well to achieve profitability goals in 2024. Our aim is to continue this momentum and accelerate growth for our business on the other side of sustained profitability.

Now let me turn the call back to Andrew for some closing comments. Thanks, Scott. As always, I’ll close with some commentary on Clover Assistant. From our own MA plan to the future of the non-insurance segment, what gives us great confidence in our strategy is that Clover Assistant is continually demonstrating that arming physicians with the right data helps them make the right decisions. And when they do that, the patient gets better outcomes and Medicare Advantage plans get better medical economics. We continue to derive great value from our technology with over 1000 basis points of MCR improvement for returning members whose PCPs use Clover Assistant as compared to those who do not. Last month, we published an in-depth analysis, further highlighting CA’s clinical efficacy, showing how clinicians using our technology are diagnosing and managing diabetes earlier, resulting in improved patient outcomes.

Diabetes is a very common disease in the Medicare population that unfortunately can result in many severe complications. That’s why diabetes care has been an important focus of Clover Assistant from its inception. And in our diabetes research paper, we outlined how the use of CA is associated with earlier diagnosis, earlier treatments, a reduction in hyperglycemia and hypoglycemia, plus reduced treatment with insulin. During our recent Clover Assistant Showcase, we put on display the incredible impact and efficacy we see from our platform. We demonstrated how we’re leveraging new advancements in AI and machine learning so that clinicians have the information they need to better care for their patients, and how we’re increasing accessibility to the platform through deep EHR integration.

Most importantly, we shared in-depth analysis of how Clover Assistant is associated with earlier identification and management of chronic conditions to illustrate how we’re improving patient care coordination through timely clinical insights. Lastly, and what’s even more exciting than our current results is the untapped potential of our platform going forward. We’ve shared in the past that we currently have over 100 machine learning models in active use alongside dozens of active or patent-pending technologies and algorithms. We’re constantly launching and testing new features as Clover Assistant is always learning and always improving. Our conviction in our technology is such that we have based our entire model upon it, and we believe we are the only managed care organization whose entire focus is on managing Medicare risk through AI powered physician focused software.

We’ve made plenty of comments today, demonstrating the strength of the Clover model and our exciting progress on our push towards sustained profitability. I’m proud of all we’ve been able to accomplish three quarters into the year. And while we have one more quarter to go, I applaud the entire Clover team for the great momentum we’ve generated so far this year. With that, let’s move on to Q&A.

See also 20 Most Searched Products on Amazon and 20 Countries That Eat Chocolate the Most.

Q&A Session

Operator: [Operator Instructions] Our first question comes from Jason Cassorla, Citi.

Jason Cassorla: Great. Thanks. And, good afternoon. Just a quick clarification on the CMS settlement. You said you have $157 million that’s due in the fourth quarter. Just making sure I heard that right. And then it sounds like you noted you wouldn’t need to raise additional capital, but just given the implied fourth quarter EBITDA losses within guidance to settlement dollars. Can you just maybe help us or help bridge your cash position over the next few quarters would be helpful. Thanks.

Scott Leffler: Yes. This is Scott. I’ll take that question. So yes, you heard that right. The settlement that we’re anticipating in Q4 was a total of $147 million, a little over $50 million of that relates to our share loss under the program – and then the remainder is just related to the working capital dynamics into the program, where international desettlement you pay back a certain amount of working capital that was advancing the program. But in terms of a cash flow bridge, yes, I’ll just kind of reiterate our expectation that we have no need for operating capital certainly at least for 2023. And as I think we indicated, our objective is to reach profitability and cash flow positivity without needing any incremental capital in 2024 in future years.

As far as cash flow bridge, I mentioned we do – we finished the quarter with $308 million of cash and cash equivalents and investments as we parent entity and unregulated sub level. And so that settlement amount is due to CMS would come out from that – and then to the extent that we do continue to deliver an EBITDA losses in Q4 going forward, it would come out of that amount as well. Although, obviously, we continue to look for opportunities to leverage the capital that we have remaining at the regulated entity level, and that’s kind of an organic flow that occurs over time. But in general, we are comfortable with our capital position now and again, look to a strong 2024 to inflate ourselves from requiring any further capital.

Jason Cassorla: Okay. Got it. Thanks. Helpful. And maybe just a follow-up. I wanted to ask about utilization trends in the quarter. Obviously, a strong result with the 78.5% MA MCR. But it looks like medical cost per member per month grew about 11% year-over-year. I know you’re more than covering that with a 22% revenue PMPM. But just curious on what you saw on the utilization front, if there’s any caveats that are driving that year-over-year medical cost per member per month trend versus kind of the 2% to 3% you were doing in the first and second quarter would be helpful. Thanks.

Scott Leffler: Yes. So I’ll comment on that. First, at a high level, it tells you from a utilization standpoint, – we’re not seeing anything very different from what we’ve seen earlier in the year. And as a reminder, when we reported Q1 and Q2, we indicated that we were seeing fairly benign trends from a utilization standpoint. On the year-over-year increase in PMC and MedEx that you’re referencing is distorted a little bit by something that happened last year where we had some favorable PPD effects in our MedEx in Q3 of last year which distorts the top a little bit. I think what’s more representative, and we tried to anchor people last quarter and this quarter now, instead of to any one quarter, looking at our year-to-date performance as being more representative of the overall performance this year, especially compared to last year.

And so as we’ve said in our prepared comments, we’re running at about an 81% MCR on a year-to-date basis. And when you look at the year-to-date PMPM, MedEx is only up about 5%, which is more representative of the benign utilization trend that I referenced.

Operator: Our next question comes from John Pinney, Canaccord Genuity.

John Pinney: Hi. John Penny on for Richard Close. Thanks for the question. Just want to talk about the applied adjusted EBITDA ramp in fourth quarter. Can you just possibly flesh that out? And what exactly you’re expecting? I assume some increased utilization, but any additional color would be great. Thanks.